Allos Therapeutics to Present at the 4th Annual Citi Biotech Day

Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company�s senior management will present a corporate overview on Wednesday, April 1 at 10:00 a.m. Eastern Time at the 4th Annual Citi Biotech Day Conference in New York City.

There will be a live webcast of the presentation, which will be accessible through a link posted on the home page and investor relations section of the Allos website. The webcast will be available for replay through April 10, 2009.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer. The Company�s lead product candidate, pralatrexate, is a novel targeted antifolate designed to accumulate preferentially in cancer cells. In February 2009, the Company announced the final results from PROPEL, the Company�s pivotal Phase 2 trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The PROPEL trial was conducted under an agreement reached with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment process. Based on the results of the PROPEL trial, in March 2009 the Company submitted a New Drug Application to the FDA for the use of pralatrexate for the treatment of patients with relapsed or refractory PTCL. The Company is investigating pralatrexate in patients with peripheral T-cell lymphoma, non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types; and it currently retains exclusive worldwide rights to pralatrexate for all indications. For additional information, please visit www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024